Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Identifying novel therapeutic targets is crucial for treating clear cell ovarian cancer.
• Small molecules targeting candidate dependencies may represent viable therapeutic strategies.

Purpose of the Study:

• To investigate the therapeutic potential of targeting EGLN1 (prolyl hydroxylase domain-containing protein 2) in clear cell ovarian cancer.
• To explore the relationship between EGLN1, HIF1A, and cancer cell proliferation.

Main Methods:

• Genome-scale loss-of-function screens were conducted in numerous cancer cell lines.
• The effects of EGLN1 inhibition (genetic and pharmacologic) on cancer cell proliferation were assessed.
• The role of HIF1A in EGLN1 dependency was investigated through gene deletion studies.

Main Results:

• EGLN1 knockout reduced proliferation in a subset of clear cell ovarian cancer cell lines.
• These cell lines were sensitive to the pan-EGLN inhibitor FG-4592.
• FG-4592 response was dependent on HIF1A, indicating EGLN1 negatively regulates HIF1A.

Conclusions:

• EGLN1 is a potential therapeutic target in clear cell ovarian cancer.
• Ovarian clear cell tumors susceptible to EGLN1 inhibition require intact HIF1A.
• Targeting EGLN1 presents a promising strategy for clear cell ovarian cancer treatment.